Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT).

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Richardson, PG; Soiffer, R; Antin, JH; Vredenburgh, J; Kurtzberg, J; Martin, PL; Hockenbery, D; Steinbach, G; Murray, K; Vogelsang, G; Chen, A; Warren, DL; Momtaz, P; Wei, LJ; Jin, Z; Rifai, N; Bradwin, G; Iacobelli, M; McDonald, GB; Guinan, EC

Published Date

  • November 16, 2002

Published In

Volume / Issue

  • 100 / 11

Start / End Page

  • 112A - 112A

Published By


  • 1

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 44th Annual Meeting of the American-Society-of-Hematology

Conference Location


Conference Start Date

  • December 6, 2002

Conference End Date

  • December 10, 2002